Medimetriks Report issue

Contributed to NME For profit Phase 2 Phase 4
Founded: Fairfield NJ United States (2008)
Status: No NME R&D (2008)

Organization Overview

First Clinical Trial
2014
NCT02168478
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Medimetriks Pharmaceuticals | Medimetriks Pharmaceuticals, Inc | MEDIMETRIKS PHARMS | Noah Rosenberg, MD

Active Ingredients

Marketed Drugs (4)

betaxolol (kerlone) (2001)

ciclopirox (loprox) (1982 NDA)

fluocinolone acetonide (synalar) (1963 NDA)

neomycin (1963)

Drugs in Phase 4 Trials (4)

fluocinolone acetonide (synalar) (1 trial)

neomycin (1 trial)

sodium chloride (1 trial)

sodium monododecyl sulfate (1 trial)

Drugs in Phase 2 Trials (1)

Difamilast (1 trial)

Indications

Approved Indications


 

Dermatitis, Seborrheic

Melanosis

Onychomycosis

Skin Diseases, Eczematous

Uveitis, Posterior

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 5